Clinical Trial Update: Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of MT-3724 in relapsed or refractory diffuse large B-cell lymphoma and related B-cell hematologic malignancies; the study is terminated with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blood Cancer
• Diffuse Large B-cell Lymphoma
• Hematological Malignancy
• Leukemia Lymphocytic Chronic B-cell
• Non-hodgkin B-cell Lymphoma
• Small Lymphocytic Leukemia

Drugs mentioned

• MT-3724

Snippet

Sponsor: Molecular Templates, Inc. | Conditions: Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-08-18